A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer

John M. Bennett, Patrick Byrne, Ajit Desai, Charles White, Ronald DeConti, Charles Vogel, Edward Krementz, Franco Muggia, James Doroshow, David Plotkin, Harvey Golomb, Hyman Muss, Harvey Brodovsky, Richard Gams, Lee Roy Horgan, Shelley Bryant, Arnold Weiss, Kenneth Cartwright, Gary Dukart

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF). Seventy-one percent of all patients were postmenopausal and 44% of CNF patients and 57% of CAF patients were estrogen receptor (ER) negative. Slightly over 30% of all patients had received hormonal therapy or chemotherapy in an adjuvant setting. Hematologic toxicity was similar in regard to platelet counts but slightly lower nadirs were experienced with CNF therapy than with CAF. However, there were fewer dosage decreases with CNF. Significantly less nausea and vomiting were observed with the CNF regimen compared to CAF. Moreover, alopecia was reduced appreciably in patients who received CNF. The response rate to CNF for the first 38 eligible and evaluable patients was 42%, and for 53 eligible and evaluable patients who received CAF the response rate was 45%, a non-significant difference. Median response durations were similar also, 140 days for CNF and 168 days for the CAF regimen. Time to treatment failure was similar for both regimens. CNF is an effective regimen for patients with advanced breast cancer, with less toxicity than CAF.

Original languageEnglish (US)
Pages (from-to)179-185
Number of pages7
JournalInvestigational New Drugs
Volume3
Issue number2
DOIs
StatePublished - Jun 1985

Keywords

  • Adriamycin
  • advanced breast cancer
  • combination chemotherapy
  • Novantrone

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Fingerprint Dive into the research topics of 'A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Bennett, J. M., Byrne, P., Desai, A., White, C., DeConti, R., Vogel, C., Krementz, E., Muggia, F., Doroshow, J., Plotkin, D., Golomb, H., Muss, H., Brodovsky, H., Gams, R., Horgan, L. R., Bryant, S., Weiss, A., Cartwright, K., & Dukart, G. (1985). A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Investigational New Drugs, 3(2), 179-185. https://doi.org/10.1007/BF00174167